Vol 72, No 2 (2021)
Clinical vignette
Published online: 2021-01-19
Efficacy of multimodal anticancer therapy in the course of pancreatic neuroendocrine carcinoma
12
, 2, 21, 21, 2, 21
, 2, 21, 21, 2, 21
Abstract
Not required for Clinical Vignette.
Keywords: neuroendocrine tumoursPRRTpNECsomatostatin analogue
References
- Zhang MY, He Du, Zhang S. Pancreatic neuroendocrine tumors G3 and pancreatic neuroendocrine carcinomas: Differences in basic biology and treatment. World J Gastrointest Oncol. 2020; 12(7): 705–718.
- Lokesh KN, Anand A, Lakshmaiah KC, et al. Clinical profile and treatment outcomes of metastatic neuroendocrine carcinoma: A single institution experience. South Asian J Cancer. 2018; 7(3): 207–209.
- Lorenzoni A, Capozza A, Artale S, et al. Impressive Response to Tandem Treatment With [90Y]DOTATOC and [177Lu]DOTATOC in Grade 3 Pancreatic Neuroendocrine Carcinoma. Clin Nucl Med. 2018; 43(7): 506–508.
- Alese OB, Jiang R, Shaib W, et al. High-Grade Gastrointestinal Neuroendocrine Carcinoma Management and Outcomes: A National Cancer Database Study. Oncologist. 2020; 25(5): e877.
- Rogowski W, Wachuła E, Gorzelak A, et al. Capecitabine and temozolomide combination for treatment of high-grade, well-differentiated neuroendocrine tumour and poorly-differentiated neuroendocrine carcinoma - retrospective analysis. Endokrynol Pol. 2019; 70(4): 313–317.
- Montanier N, Joubert-Zakeyh J, Pétorin C, et al. The prognostic influence of the proliferative discordance in metastatic pancreatic neuroendocrine carcinoma revealed by peptide receptor radionuclide therapy: Case report and review of literature. Medicine (Baltimore). 2017; 96(6): e6062.
